Acelyrin Adopts Poison Pill

Acelyrin Adopts Poison Pill to Ward Off Tang Capital Buy
The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an attempt to disrupt a merger with Alumis.
Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’
President Trump’s nominee to run the FDA secured the Senate HELP Committee’s backing. Elsewhere, Sutro cut jobs and a cell and gene therapy pilot appeared to survive.
Acelyrin Adopts Poison Pill as Tang Capital Partners Builds Stake
The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will become exercisable only if any person acquires 10% or more of Acelyrin's outstanding common stock.
Acelyrin adopts poison pill as Tang Capital Partners raises stake
Acelyrin (NASDAQ:SLRN) announced Thursday a decision to adopt a limited-duration stockholder rights plan, also known as a poison pill, after Tang Capital Partners rapidly accumulated 8.8% of the company stock following an unsolicited acquisition offer.
Drug developers Pliant and Acelyrin adopt poison pill provisions to fend off activist investor
Pliant and Acelyrin adopt poison pill measures to counter activist investor Kevin Tang's stock accumulation, aiming to prevent hostile takeovers.
Fierce Biotech2d
Pliant, Acelyrin resort to ‘poison pills’ as threat of Concentra buyout looms
With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up ...
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
The Rights Plan is effective immediately and will expire on March 12, 2026. ACELYRIN stockholders do not need to take any further action at this time.
BioSpace2d
Pliant Pops Poison Pill as Concentra Threat Looms
Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...
Fierce Biotech12d
Acelyrin doubles down on Alumis merger after deciding Concentra's surprise offer 'not superior'
Acelyrin has declined a surprise offer from Concentra Biosciences, and is instead p | Acelyrin consulted with independent ...
Acelyrin: Potential Buyout Led By Concentra Biosciences
Concentra Biosciences offers $3/share + CVR for Acelyrin, outperforming Alumis' bid. Read why I rate SLRN stock a Sell at ...
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC ...
Acelyrin, Alumis reaffirm strategic, financial rationale of proposed merger
Alumis (ALMS) and ACELYRIN (SLRN) reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage ...